Allergan, NY End Antitrust Fight Over Dementia Drug
Law360, Washington (November 30, 2015, 4:33 PM EST) -- Allergan and New York state have settled an antitrust suit that accused the drugmaker of steering patients away from one of its dementia drugs and toward another to avoid competition with generic versions that were coming to market.
New York Attorney General Eric Schneiderman agreed to end his investigation into last year's decision by Actavis, which has since merged with Allergan, to stop making Namenda IR soon before generic versions of the immediate-release drug were to debut, and to switch patients to its longer-acting Namenda XR, which has no generic competitor on the horizon. Allergan agreed to pay the attorney general...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!